We recently published our article 5 Best Cheap AI Medicine Stocks to Buy Now. To read the full article, head on to 10 Best Cheap AI Medicine Stocks to Buy Now. In this piece, we take a closer look at Butterfly Network Inc. (NYSE:BFLY) to examine its latest developments, pipeline progress, and why it continues to draw attention from investors.
Artificial intelligence is no longer limited to chatbots, digital advertising and Silicon Valley experiments. It is moving into hospitals, laboratories and pharmaceutical research, where algorithms are helping scientists discover potential medicines, interpret medical images, analyze genetic information and identify treatments suited to individual patients.
Interestingly, the term “artificial intelligence” was introduced in 1956, but medical AI took decades to become commercially practical. Modern healthcare systems now generate enormous amounts of clinical, imaging and genomic data—the exact type of information machine-learning models are designed to analyze.
Why Medicine Could Be AI’s Next Major Market
Drug development has traditionally required years of research, costly clinical trials and thousands of unsuccessful experiments. AI drug discovery platforms cannot eliminate those risks, but they can help researchers screen molecules, predict biological interactions and prioritize the most promising candidates before expensive trials begin.
Medical imaging has also become one of the earliest real-world applications of artificial intelligence in healthcare. AI-powered diagnostics can assist doctors in detecting abnormalities, improving image quality and prioritizing urgent cases. Meanwhile, precision medicine platforms are using clinical and genomic data to help match patients with more appropriate treatments.
These developments have encouraged investors to search for the best AI healthcare stocks, AI biotech stocks and medical AI companies positioned to benefit from the industry’s long-term expansion.
A Low Share Price Does Not Always Mean Cheap
A stock trading below $10 may look affordable, but it can still be overvalued if the company generates little revenue, loses money and repeatedly issues new shares. On the other hand, a profitable healthcare technology company trading above $50 may be undervalued when its earnings, cash flow and competitive advantages support a higher valuation.
The most attractive cheap AI medicine stocks therefore combine genuine medical applications with reasonable valuations, sufficient cash reserves, improving financial performance and meaningful long-term growth opportunities.
Finding the Best AI Medicine Stocks
This ranking evaluates NYSE- and Nasdaq-listed companies based on their AI exposure, valuation, revenue growth, financial strength, clinical potential and competitive position. Higher-risk companies were penalized for heavy losses, shareholder dilution, limited cash runways and uncertain paths to profitability.
The countdown begins with the most speculative AI medicine stock at No. 10 and ends with the strongest overall risk-adjusted pick at No. 1. These companies operate across AI drug discovery, precision medicine, genomic analysis, medical imaging, digital health and clinical research—some of the most promising fields where artificial intelligence could reshape modern healthcare.
CHECK THIS OUT: Top 10 Healthcare Stocks to Buy With $1000 in 2026 and 10 Best Medicine Stocks That Could Make Investors 100% Richer.
Our Methodology
For the 10 Cheap AI Medicine Stocks That Could Make You a Millionaire, we ranked each company based on its valuation, medical AI exposure, revenue growth, financial strength, clinical potential and overall investment risk.
5 Best Cheap AI Medicine Stocks to Buy Now
5. Butterfly Network Inc. (NYSE:BFLY)
Butterfly Network, Inc. (NYSE: BFLY) takes fifth place as one of the most unusual AI healthcare stocks in the ranking. The company is attempting to replace bulky and expensive traditional ultrasound equipment with portable semiconductor-based imaging systems connected to cloud software and artificial intelligence.
Its handheld ultrasound devices can potentially extend medical imaging beyond specialized radiology departments. Doctors, nurses, emergency responders and medical students can use portable imaging at the point of care. This could be particularly valuable in smaller hospitals, ambulances, rural clinics and developing markets where full-sized imaging systems are difficult to obtain.
The company is also expanding its software and licensing operations. Compass AI is designed to support point-of-care ultrasound programs by helping healthcare institutions manage clinical workflows, quality, documentation and device utilization. The broader Embedded strategy allows partners to incorporate the company’s ultrasound technology into other products.
Second-quarter 2026 revenue increased 39% to $32.6 million, while gross margin expanded to approximately 71%. Software and services revenue reached $16.9 million and represented more than half of total quarterly revenue. This shift matters because recurring software and licensing income can carry more attractive margins than hardware sales. The company ended June with approximately $124.7 million in cash and equivalents. The quarterly filing detailed the revenue mix, losses and available cash.
At approximately $7.36 per share, the stock remains accessible, but its market capitalization approaches $2 billion. That valuation requires substantial future growth. The company also continues to lose money, with a second-quarter net loss of approximately $12.9 million.
The investment thesis depends on portable ultrasound becoming a standard medical tool and software revenue continuing to expand. If the company can convert its technological lead into widespread hospital adoption, the long-term opportunity could be considerable. Failure to achieve profitability would leave shareholders vulnerable to additional financing and dilution.
YOU MUST READ THIS: Top 10 Healthcare Stocks to Buy With $1000 in 2026
Disclosure: No relevant interests to disclose. This article was originally published on BioTech HealthX.
